Find a Clinical Trial | Tufts Medicine

Filter

Showing 41 - 50 out of 69

EA3191

EA3191 - A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

Head and neck cancer

All genders

18-79

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

EAQ202

EAQ202, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Cancer

All genders

18-39

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

Effects of BCR-ABL tyrosine kinase inhibitors on platelets and white blood cells

All genders

18+

Recruiting now

CardioVascular Center

Learn more

Lung CA Dental

Evaluating periodontal health in subjects with lung cancer prior to cancer therapy and monitoring impact of periodontal disease on treatment efficacy and side-effects.

Non-small cell lung cancer

All genders

45+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

EXPAND TAVR II

Evolut™ EXPAND TAVR II Pivotal Trial

Heart failure

All genders

65+

Recruiting now

CardioVascular Center

Learn more

FACT-CRT

Factors Associated with Response to Cardiac Resynchronization Therapy in Heart Failure Patients with Non-LBBB ECG Pattern

Cardiac failure, Heart failure

All genders

18+

Recruiting now

CardioVascular Center

Learn more

HER2 Negative Breast Cancer

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Breast cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

IMGN857-0421, Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)

Fallopian tube cancer, Ovarian cancer, Peritoneal cancer

All genders

18+

Recruiting now

Cancer Center

Learn more

Protect IV

Impella® Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial

Heart failure

All genders

18-90

Recruiting now

CardioVascular Center

Learn more

Multi-spectral imaging

Label-free, multi-scale imaging for improved detection of ovarian cancer metastases

Ovarian cancer

Female

18-99

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more